New York, May 22, 2026, 09:08 EDT
Akari Therapeutics shares were indicated sharply higher before the Nasdaq open on Friday, after the oncology biotech said its lead cancer drug candidate showed positive preclinical activity in KRAS-mutated pancreatic cancer models and priced a $5.5 million private placement. The stock closed Thursday at $5.14, up 49.85%, and was quoted at $10.15 in premarket trading at 8:39 a.m. EDT, according to StockAnalysis.
The move matters because Akari is still a preclinical company, not a revenue-producing drugmaker. Its latest data give investors a fresh reason to look at AKTX-101, while the financing gives the company more cash to push the program toward human testing.
Akari said AKTX-101, an antibody-drug conjugate, or ADC — a cancer drug designed to carry a toxic payload more directly to tumor cells — showed synergistic cell-killing activity when paired with adagrasib, a KRAS inhibitor, in pancreatic cancer cell lines with KRAS G12D and G12C mutations. KRAS is a gene involved in cell growth, and mutated forms have been found in cancers including pancreatic, colorectal and non-small cell lung cancer.
The company said the combination effect was not seen with comparator TROP2 ADCs using topoisomerase I inhibitor payloads, which instead showed antagonism when paired with adagrasib. That is the part the market seized on: Akari is trying to show its PH1 payload works differently from better-known TROP2 ADCs.
Chief Executive Abizer Gaslightwala said the data suggested PH1 may offer a “fundamentally differentiated mechanism.” Dr. Satyajit Mitra, Akari’s executive director and head of oncology, said KRAS mutations have been “incredibly difficult to drug.” Akari Therapeutics
Akari said it has begun IND-enabling studies — the studies needed before seeking U.S. clearance to test a drug in humans — and is targeting the start of a Phase 1 first-in-human trial by mid-2027. Phase 1 is the first stage of clinical testing and usually focuses on safety and dose.
The financing came the same day. Akari said it agreed to sell 1,470,588 unregistered American depositary shares, or pre-funded warrants in place of ADSs, plus Series H, I and J warrants, at $3.74 per ADS. It expects about $5.5 million in gross proceeds before fees, with closings scheduled in three tranches from May 27 to July 15.
Gaslightwala said the financing reflected “deep conviction” from long-term strategic investors. The company said proceeds would be used for working capital and general corporate purposes, including advancement of AKTX-101 toward Phase 1 testing. Akari Therapeutics
The cash issue is not a side note. In its quarterly report filed May 19, Akari said it had $2.8 million in cash at March 31 and an accumulated deficit of $279.0 million. It also said that cash was not enough to fund operations for the year after the financial statements were issued, raising “substantial doubt” about its ability to continue as a going concern. Akari Therapeutics
For the first quarter, Akari reported a net loss of $14.5 million, compared with a loss of $3.7 million a year earlier. The company said it had not generated revenue to date.
Competition is already real in the TROP2 ADC field. Gilead’s Trodelvy is a TROP2-directed antibody and topoisomerase inhibitor conjugate, while AstraZeneca and Daiichi Sankyo’s Datroway won U.S. approval in 2025 as a TROP2-directed antibody and topoisomerase inhibitor conjugate for a type of metastatic breast cancer.
The risk is that Akari’s latest findings are still preclinical. Lab results can fail to translate into human benefit, and a sharp move in a thinly traded biotech can reverse quickly if traders focus on dilution from the new ADSs and warrants, clinical timing, or the company’s need for more capital.
Nasdaq’s regular stock-market session runs from 9:30 a.m. to 4:00 p.m. Eastern time, with premarket trading before that window; Nasdaq lists Memorial Day, Monday, May 25, as a market holiday. Friday is therefore a normal trading day, but the long weekend may thin liquidity.
